

Boston Scientific Announces Third Quarter Results

(October 14, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its third quarter ended September 30, 2005 and provided revised revenue and earnings-per-share guidance for the fourth quarter and full year of 2005.

Third Quarter Financial Results:

Net sales for the third quarter were \$1.511 billion as compared to \$1.482 billion for the third quarter of 2004, an increase of two percent. Worldwide coronary stent sales for the third quarter were \$633 million as compared to \$686 million for the third quarter of 2004. Worldwide sales of TAXUS® paclitaxel-eluting coronary stent systems were \$601 million.

During the quarter, the Company recorded special charges of \$616 million, net of tax. The after-tax special charges for the quarter consisted primarily of \$598 million related to the previously announced settlement agreement with Medinol. The reported net loss for the quarter, including net special charges, was \$269 million, or \$0.33 per share.

Net income for the quarter, excluding net special charges, was \$347 million, or \$0.42 per share, as compared to \$404 million, or \$0.47 per share in the third quarter of 2004.

Fourth Quarter and Full Year 2005 Guidance:

For the fourth quarter, worldwide sales are expected to range between \$1.550 billion and \$1.590 billion. Earnings per share for the fourth quarter, excluding net special charges, are expected to range between \$0.40 and \$0.44 per share.

Worldwide sales for the full year are expected to range between \$6.293 billion and \$6.333 billion. Earnings per share for 2005, excluding net special charges, are expected to range between \$1.81 and \$1.85 per share.

"During the quarter, we maintained our drug-eluting stent leadership position and experienced significant growth in international TAXUS

<https://news.bostonscientific.com/news-releases?item=58704>